Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis

Main Article Content

Alessandro Laganà
Array

Giovanni Manfredi Assanto
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy

Mauro Passucci
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy

Cristina Santoro
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy

Antonio Chistolini
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy

Keywords

VTE Predict score, Direct oral anticoagulants (DOACs), Key words: direct oral anticoagulants, thrombophilia, thromboembolism, venous thrombosis

Downloads

Download data is not yet available.


Abstract 655
PDF Downloads 103
HTML Downloads 7

References

1. De Winter MA, Büller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, Kakkar AK, Middeldorp S, Raskob GE, Sørensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M; VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 Apr 7;44(14):1231-1244.

2. Laganà A, Assanto GM, Masucci C, et al. Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up. Mediterr J Hematol Infect Dis. 2024;16(1):e2024020.

Article Sidebar

PDF HTML
Published
Apr 30, 2024
DOI https://doi.org/10.4084/MJHID.2024.047

Article Details

How to Cite

Laganà, A. (2024) “Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis ”, Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024047. doi: 10.4084/MJHID.2024.047.
Issue
Vol. 16 No. 1 (2024): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.